Qualia Mind Neurable Headphones Study
We are seeking 5 participants, age 21–60, to take part in a 4-week pilot study evaluating the effects of Qualia Mind 2.0 on cognitive functioning as measured by the Neurable MW75 Neuro Headphones.
The purpose of this study is to explore how Qualia Mind 2.0 supplementation may influence cognitive performance and self-reported focus, using both objective neurodata and subjective feedback. This is an open-label study, meaning all participants will receive the active product.
Participants will wear the MW75 Headphones daily for the first week to establish baseline readings. For the following 3 weeks, participants will take Qualia Mind 2.0 (5 days on, 2 days off) while continuing daily headphone use. Surveys will assess cognitive changes using Neurable’s cognitive scores and a custom 11-point self-report scale.
Pre-screening surveys are used solely to determine eligibility for participation. Data will be securely stored on Qualia Life Sciences servers, accessible only to authorized personnel.
*US only
*This study is being conducted by Qualia Life Science
REQUIREMENTS AND CRITERIA:
Inclusion Criteria:
- Adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities;
- Resides in the United States;
- Willingness to take the study product and use the Neurable MW75 headphones.
- Willingness to adhere to dietary supplement instructions and complete questionnaires, records, and diaries associated with the study;
- Agree to provide a valid cell phone number and are willing to receive communications through text;
- Able to provide voluntary, written, informed consent to participate in the study;
- Willing to not begin taking any new supplements while testing this product and continue taking any supplements they are currently using regularly
Exclusion Criteria:
- Pregnant, trying to become pregnant, or breastfeeding;
- Existing psychiatric disorder, including depression;
- Reports current use of anticoagulants, chemotherapy, immunotherapy, MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines;
- Reports a diagnosis of liver or kidney disease
- Unable to provide a valid physical shipping address;
- Unable to read and understand English;
- Lack of reliable daily access to the internet;
- Inability to tolerate caffeine or unwillingness to take a caffeine-containing product;
- Allergy, sensitivity, or intolerance to the investigational product’s active or inactive ingredients;
- Individuals who are cognitively impaired and/or who are unable to give informed consent;
- Any medical condition that would require their doctor’s approval prior to starting a dietary supplement.